fashion -WSS

fashion

author：focus 2025-09-29 12:30:20 - browse：8952

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

A group of advisers to the Food and Drug Administration voted in favor of Alnylam Pharmaceuticals’ treatment for a debilitating heart disease Wednesday, but only after a day-long debate challenging whether the drug’s modest observed effects were actually meaningful for patients.

The group of independent experts voted 9-3 that the benefits of Alnylam’s drug, called patisiran, outweighed its risks for patients with ATTR-CM, a progressive disease that leads to fatal heart failure if left untreated. The FDA, which is not required to follow the advice of advisers, is expected to make a final decision on patisiran by Oct. 8.

“It’s like a light wind blowing in favor of patisiran over placebo,” said David Cella, a neurologist at the Northwestern University Feinberg School of Medicine who voted in favor of patisiran. David Moliterno, a cardiologist at the University of Kentucky, added that “the good news in this story is that while there may be a small benefit, it doesn’t look like there’s a signal for harm.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Driven by the pandemic, applicants flood public health schools

knowledge

WSS

J&J to emphasize cancer drugs, stop much of its vaccine research

Key lawmaker blasts Congress’ efforts on addiction: ‘Shame on us’

Tesla recalling nearly 16,000 of its 2021

Awakening the world to the whoosh: A patient's crusade

DeSantis talks Trump, trans issues and 'what wokeness is'

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

entertainment

fashion

entertainment

As demand for Covid shots wanes, Moderna seeks its next success

Texas Department of Public Safety speaks out on migrant abuse allegations

Medical records are filled with copy

Why Congress must ban federal programs from using QALYs

The high cost of giving birth even with insurance

CDC director unscathed in first congressional testimony

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Tocagen's brain cancer gene therapy trial continues. Investors worry

In age of alternative facts, a scholarly course on calling out crap

'Stay indoors': Escaped wild animal on the loose in Berlin prompts urgent citywide search

hotspot

How to pay for weight loss drugs and save Medicare

Key lawmaker blasts Congress’ efforts on addiction: ‘Shame on us’

7 more heat

Disappointing trial forces Pfizer to pivot on obesity medicine plans

U.K. Biobank has 500,000 peoples' genome sequences available

With clinical trial data readouts, here's how to spot spin

entertainment

knowledge

knowledge

leisure time